Switch theme
Sign up to access all valuation multiples
Ulisse Biomed SpA is a healthcare biotech company. It is engaged in developing medical diagnostics, theranostics, and therapeutics solutions. The company has three technology platforms, namely, Sagitta for molecular diagnostics, NanoHybrid for theranostics and diagnostics, and Aptavir for therapeutics.
2015
10
LTM Revenue n/a
LTM EBITDA n/a
$19.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ulisse Biomed has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Ulisse Biomed achieved revenue of $0.1M and an EBITDA of -$2.3M.
Ulisse Biomed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ulisse Biomed valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.2M | $0.1M | XXX | XXX | XXX |
| Gross Profit | $0.2M | -$0.2M | XXX | XXX | XXX |
| Gross Margin | 112% | -154% | XXX | XXX | XXX |
| EBITDA | -$1.1M | -$2.3M | XXX | XXX | XXX |
| EBITDA Margin | -678% | -1815% | XXX | XXX | XXX |
| Net Profit | -$0.6M | -$1.4M | XXX | XXX | XXX |
| Net Margin | -414% | -1108% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Ulisse Biomed's stock price is EUR 1 (or $1).
Ulisse Biomed has current market cap of EUR 19.0M (or $20.5M), and EV of EUR 17.9M (or $19.2M).
See Ulisse Biomed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19.2M | $20.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Ulisse Biomed has market cap of $20.5M and EV of $19.2M.
Ulisse Biomed's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Ulisse Biomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ulisse Biomed and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $19.2M | XXX | XXX | XXX |
| EV/Revenue | 151.4x | XXX | XXX | XXX |
| EV/EBITDA | -8.3x | XXX | XXX | XXX |
| P/E | -7.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -12.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpUlisse Biomed's NTM/LTM revenue growth is n/a
Ulisse Biomed's revenue per employee for the last fiscal year averaged $13K, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Ulisse Biomed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ulisse Biomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ulisse Biomed and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -19% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1815% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 117% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $13K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1915% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ulisse Biomed acquired XXX companies to date.
Last acquisition by Ulisse Biomed was XXXXXXXX, XXXXX XXXXX XXXXXX . Ulisse Biomed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ulisse Biomed founded? | Ulisse Biomed was founded in 2015. |
| Where is Ulisse Biomed headquartered? | Ulisse Biomed is headquartered in Italy. |
| How many employees does Ulisse Biomed have? | As of today, Ulisse Biomed has 10 employees. |
| Is Ulisse Biomed publicy listed? | Yes, Ulisse Biomed is a public company listed on MIL. |
| What is the stock symbol of Ulisse Biomed? | Ulisse Biomed trades under UBM ticker. |
| When did Ulisse Biomed go public? | Ulisse Biomed went public in 2021. |
| Who are competitors of Ulisse Biomed? | Similar companies to Ulisse Biomed include e.g. Zomedica, AnteoTech, Proteomics International, Biohit. |
| What is the current market cap of Ulisse Biomed? | Ulisse Biomed's current market cap is $20.5M |
| What is the current revenue growth of Ulisse Biomed? | Ulisse Biomed revenue growth between 2023 and 2024 was -19%. |
| Is Ulisse Biomed profitable? | Yes, Ulisse Biomed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
